Microgynon ED

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microgynon ED

Quick Facts Overview

Property Description
Active ingredient Ethinyl Estradiol and Levonorgestrel
Form Tablet
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of Pregnancy
Origin Synthetic hormone

What Type of Medicine is Microgynon ED?

Microgynon ED is classified as a Combined Hormonal Contraceptive (CHC), recognized as a highly effective prescription-only medicine whose primary purpose is the prevention of pregnancy. Its use is clinically recognized for providing effective, reversible contraception for women of reproductive potential. This medication is an Oral Contraceptive Pill (OCP) that acts systemically, belonging to the pharmacological group of progestogens and estrogens in fixed combinations. This combination of Levonorgestrel and Ethinyl Estradiol is indicated for use by females of reproductive potential to prevent pregnancy. The specific "ED" (Every Day) designation refers to the regimen pack, simplifying the continuous daily cycle of oral administration in the form of a tablet.

The Active Components: Ethinyl Estradiol and Levonorgestrel

The core identity of this drug is defined by its two active ingredients: Ethinyl Estradiol and Levonorgestrel, confirming it as a combination product. These substances are synthetic hormone analogues, comprising a synthetic estrogen and a synthetic progestin, respectively. The combination works by preventing a woman’s egg from fully developing each month, effectively blocking fertilization. The formulation is considered a second-generation contraceptive, distinguishing it from newer or older formulations. Microgynon ED is further characterized as a monophasic preparation, meaning the controlled, fixed dosage of the two hormones remains constant across every active tablet, providing a consistent hormonal foundation to achieve its contraceptive benefit.

Regulatory References

  1. Birth control pills - combination: MedlinePlus

What side effects are possible with Microgynon ED?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse reactions of this combined hormonal contraceptive into frequency categories and by affected body system.

Commonly Documented Adverse Reactions

The most frequent adverse reactions noted in official labeling (classified as very common or common) include headache, nausea, vomiting, and abdominal pain. Other common effects include changes in mood or libido, breast pain, breast tenderness, and weight gain. Unscheduled bleeding or spotting is a common occurrence, particularly during the initial months of use, which often diminishes over time.

Serious Adverse Reactions and Vascular Risk

Combined hormonal contraceptives are officially associated with an increased risk of rare but serious vascular events, specifically Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), including stroke and myocardial infarction. This risk is officially documented as highest during the first year of use or when restarting treatment after a break of four weeks or more. Other rare, serious concerns documented include the potential for hepatic neoplasia (benign and malignant liver tumours).

Safety Restrictions and Contraindications

Specific safety constraints are outlined in the regulatory prescribing information. The medication is officially contraindicated for women who are smokers and over 35 years old due to a significantly increased risk of serious cardiovascular events. Contraindications also apply to individuals with a history of VTE/ATE, severe hepatic disease, or migraine with focal neurological symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific manifestations and required actions in the event of an acute overdose of Microgynon ED (Ethinyl Estradiol and Levonorgestrel).

Documented Overdose Manifestations

Feature Regulatory Statement
Common Symptoms Nausea, Vomiting, and subsequent Withdrawal bleeding (Vaginal bleeding) are the primary documented clinical signs following acute ingestion.
Severity Overdose is generally classified in regulatory documents as not likely to be life-threatening.
Population Note The manifestation of Withdrawal bleeding may specifically occur in young girls (prepubescent females) who ingest large doses of this type of combined contraceptive.

Required Emergency Actions

Feature Mandated Action
Immediate Response Individuals must seek immediate medical attention and contact a Poison Control center right away for assessment and guidance.
Antidote Status No specific antidotes are known or listed in the official prescribing information for this hormonal combination.
Treatment Protocol Management is limited to symptomatic treatment and providing necessary supportive care to address the presented manifestations, as outlined in regulatory documents.

Any suspected overdose requires urgent medical attention to ensure proper observation and supportive management consistent with regulatory guidelines.

Therapeutic Uses of Microgynon ED

What Microgynon ED Treats: Main Uses and Benefits

The primary use of this combined hormonal contraceptive is providing effective and reversible pregnancy prevention. Additionally, this medication is commonly used to manage symptoms that interfere with daily functioning.

The therapeutic domains where this medication may assist with easing symptoms include painful menstrual cramps (dysmenorrhea), excessive menstrual bleeding (menorrhagia), cycle irregularity, and mild to moderate hormonal acne. Its application supports the handling of distressing manifestations. This may assist with maintaining functional stability and supports general well-being during symptomatic phases.

“This medication is relevant in situations with significant discomfort.”

Quick Fact: Managing Menstrual Symptoms
Symptom Clusters Addressed Symptoms related to physical discomfort (cramps) and systemic imbalance (irregularity, acne)
Primary Therapeutic Benefit Provides supportive relief when the goal is to prevent conception
Secondary Benefits Contributes to easing the overall symptom load and helps improve day-to-day comfort

Regulatory References

  1. NIH MedlinePlus overview of Levonorgestrel and Ethinyl Estradiol

Eligibility and Restrictions for Use

Population Eligibility for Microgynon ED

The use of Microgynon ED (Levonorgestrel and Ethinyl Estradiol) is strictly defined by regulatory eligibility criteria, primarily indicated for females of reproductive potential seeking pregnancy prevention. Official labeling establishes numerous absolute contraindications where the medicine must not be used, largely due to systemic risk.

Key exclusions, consistent across regulatory documents, include women over 35 years of age who smoke, and individuals with current or history of thromboembolic disorders (such as Deep Vein Thrombosis or Pulmonary Embolism). The medication is also contraindicated in individuals with severe hepatic disease (including decompensated cirrhosis and liver tumors), hormone-sensitive cancers (e.g., breast cancer), uncontrolled hypertension, or specific migraine headaches with aura.

In terms of life stage, Microgynon ED is contraindicated during known or suspected pregnancy. It is not recommended for nursing mothers, as use may decrease milk production. Postpartum initiation is restricted and should not start earlier than four weeks after delivery for non-breastfeeding females. Use is not indicated for geriatric populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Microgynon ED based on effects that alter the plasma concentration and subsequent exposure of the contraceptive hormones (Ethinyl Estradiol and Levonorgestrel).

Contraindicated Combinations

The co-administration of this contraceptive with certain drug regimens for Hepatitis C, specifically those containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir), is officially contraindicated. This restriction is mandatory due to the documented risk of liver enzyme (ALT) elevations.

Pharmacokinetic Interactions

Many interactions are classified based on effects on the body's clearance pathways:

  • Enzyme Inducers: Substances like the anti-epileptics Phenytoin and Carbamazepine, as well as the herbal product St John's Wort, are documented to increase the clearance of the hormones. This outcome can significantly reduce the systemic exposure to the progestin and estrogen components, leading to diminished contraceptive efficacy.
  • Enzyme Inhibitors: Conversely, certain agents, including Azole antifungals (Itraconazole) and Macrolide antibiotics (Clarithromycin), are classified as CYP3A4 inhibitors. These substances are documented to decrease the clearance of the hormones, potentially increasing their plasma concentrations.

Impact on Co-administered Medicines

Oral contraceptives are documented to influence the clearance of other drugs, which can alter their effects. For example, co-administration may increase the plasma concentrations of medicines like Cyclosporin and Tizanidine, and can decrease the plasma concentration of Lamotrigine.

Mechanism of Action

The Microgynon ED combined hormonal formulation employs a mechanism involving the introduction of exogenous ethinylestradiol and levonorgestrel. The overall action modulates the reproductive endocrine system primarily through three mechanisms:

  1. Suppression of Gonadotropins: The hormonal components modulate the hypothalamic-pituitary-ovarian (HPO) axis. This results in the negative feedback inhibition of the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland. This suppression inhibits the LH surge, thereby arresting follicular maturation and resulting in anovulation.

  2. Cervical Mucus Alteration: Levonorgestrel alters the physicochemical properties of cervical mucus, leading to increased viscosity. This modification restricts sperm motility and ascent into the upper reproductive tract.

  3. Endometrial Changes: The progestogen and estrogen components induce histological changes in the endometrium, resulting in endometrial atrophy and cellular modifications.

These combined actions effect system-level physiological modulation that results in the contraceptive effect.

Dosage and Administration Information

The administration of Microgynon ED is based on a structured, continuous 28-day cyclic pattern. The medication is delivered via the oral route in the form of a tablet, and the fixed-dose, monophasic regimen requires one tablet taken daily at approximately the same time each day to maintain consistency.

The pack design dictates the sequence of use: administration starts with the 21 active tablets, each containing a standardized dose of 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol, which are followed immediately by the 7 hormone-free (inert) tablets. This sequential, continuous daily intake is the cornerstone of the administration protocol, ensuring no tablet-free break occurs between packs.

Administration Guidelines Summary

Instruction Scope Requirement
Route & Preparation Swallowed whole with water; must not be altered before use.
Daily Dose One tablet taken once daily.
Timing At approximately the same time each day; intake is permitted with or without food.
Procedural Start Tablet taking must begin in the sequence printed on the blister pack.

The usage protocol also includes instructions for specific procedural scenarios. For instance, detailed rules are provided for managing a missed active dose, outlining the steps required depending on the time elapsed since the dose was due. Similarly, guidance addresses the required start time for administration following childbirth or a second-trimester abortion, noting that starting later than 28 days necessitates the use of additional barrier methods for the first week.

Recent Clinical Evidence

Microgynon ED: Research Evidence Overview


Evidence for Use in Preventing Pregnancy

The primary use of this medication has been studied extensively for contraception through both short-term clinical trials and long-term observational studies. Research has examined the medication’s association with suppressing the monthly release of an egg (ovulation). In these studies, consistent use was associated with the required suppression of ovarian activity. The effectiveness in preventing unintended pregnancy is measured using the Pearl Index, derived from real-world data collected over many years. It is important to note that all oral contraceptive research shows a difference between effectiveness in highly controlled trials and effectiveness in real-world settings, often due to variations in user adherence.


Secondary Benefits and Research Gaps

This combination of hormones was evaluated in studies for secondary uses, including the management of painful menstrual cramps (dysmenorrhea) and excessive menstrual bleeding (menorrhagia). Studies utilized Randomized Controlled Trials and patient-reported outcomes, with findings describing patterns where use was associated with changes in the reported severity of pain and measured blood loss. Similar research has been conducted for mild to moderate hormonal acne, with findings indicating changes in acne severity and lesion counts over several months of use when compared to placebo.

What remains uncertain across these secondary indications is the lack of large-scale comparative evidence directly comparing this specific dose to all newer contraceptive options. Furthermore, while long-term observational studies have followed patients for years, these studies can only establish associations and cannot definitively establish causality for all long-term health trends. Limited data also exists for women with certain complex underlying medical conditions, as these populations are often not the primary focus of registration trials.

Frequently Asked Questions (FAQ)

Common questions about Microgynon ED (FAQ)


Q: Why does Microgynon ED come with 'ED' in the name?

The 'ED' in the name stands for 'Every Day'. This designation is used for the pack size and dosing schedule. It indicates that the pack contains 21 active pills plus 7 inactive (hormone-free) pills, which are designed to be taken continuously daily without a break between packs.


Q: What is the difference between Microgynon and Microgynon ED?

Microgynon is typically a 21-day pack requiring a 7-day pill-free break after the final active pill. Microgynon ED, however, is a 28-day pack that includes 7 inactive pills to facilitate continuous daily dosing. Both formulations contain the same active hormonal components (Levonorgestrel and Ethinyl Estradiol).


Q: Does Microgynon ED help with heavy or painful periods?

While the primary, officially approved use is contraception, official information notes that this medication may offer certain secondary benefits. These can include a change to more regular and lighter periods, as well as a potential decrease in period pain (dysmenorrhea). Clinical experience and research findings have noted this association.


Q: Can Microgynon ED be used for conditions other than contraception?

The primary indication for this medicine is the prevention of pregnancy. However, the combination of hormones has been clinically evaluated for secondary benefits. Official documents suggest an association with positive changes in conditions like acne and the experience of heavy or painful periods.


Q: Is it common to experience spotting or breakthrough bleeding when starting Microgynon ED?

According to official regulatory documents, yes, unscheduled bleeding or spotting is a common adverse reaction when using this medication. This is especially true during the initial first few months as the body adjusts to the hormonal input. This often diminishes over time as the body adjusts.


Q: What kind of changes to mood or weight are people most concerned about with Microgynon ED?

Official labeling lists both mood changes (including depressed mood) and weight gain as commonly reported adverse reactions associated with this type of hormonal contraceptive. These effects are documented in official labeling as common adverse reactions.


Q: How quickly do fertility levels return to normal after stopping Microgynon ED?

Stopping combined oral contraceptives, such as Microgynon ED, is generally considered to be fully reversible. Fertility is typically expected to return after the medication is discontinued. General data for this class of contraceptives suggests that many women who stop taking the pill become pregnant within 12 months, although individual results may vary.


Q: Can women who are breastfeeding use Microgynon ED?

Official regulatory information states that the use of this medicine is not recommended while breastfeeding. This is primarily because the hormones may reduce the quantity and quality of breast milk produced.


Q: What are the general guidelines for using Microgynon ED for women over 35?

The medication has a specific safety constraint: it is strictly contraindicated (must not be used) for women over 35 years of age who smoke, due to a significantly increased risk of serious cardiovascular complications. For non-smoking women over 35, the use of combined oral contraceptives is typically evaluated based on individual risk factors and a healthcare assessment.


Q: What happens if I start a new pack of Microgynon ED late?

If the inactive interval is extended, contraceptive protection may be compromised. The official product information provides a specific protocol which generally involves starting a new pack and using a backup barrier method for a specified period.


Q: What is the typical timeframe for a withdrawal bleed when taking Microgynon ED?

The bleeding experienced while on the pill is a 'withdrawal bleed.' This bleed usually starts during the time when the 7 inactive tablets are being taken. The duration of this withdrawal bleed can vary by person.


Q: Can Microgynon ED be taken continuously to skip periods?

The labeled method of use is the 28-day cyclic pattern (21 active / 7 inactive tablets). Continuous use (skipping the inactive tablets) is not the labeled method of use defined in the official prescribing information.


Q: Are headaches a common side effect when first starting Microgynon ED?

According to official documentation, headache (including migraine) is generally listed as a common adverse reaction to this medicine. While the documents do not specify if the frequency is higher upon starting, it is a known effect documented as a common adverse reaction.


Q: Does Microgynon ED cause or worsen acne?

Official side-effect profiles in some regulatory documents list acne as a common adverse reaction in certain users. These profiles state that the pill may cause or worsen acne in some individuals.


Q: What foods or drinks should be avoided while on Microgynon ED?

Official administration instructions state that the tablet can be taken with or without food. Generally, there are no specific common foods or drinks that are contraindicated or must be avoided while using this medication.


Q: Is Microgynon ED still effective if I have a stomach bug or vomiting?

If vomiting or severe diarrhea occurs within 3 to 4 hours of taking an active pill, absorption may be compromised. In this scenario, the official guidance for a missed pill applies to help maintain contraceptive efficacy.


Q: Does Microgynon ED provide protection against sexually transmitted infections (STIs)?

According to general guidance from all major regulatory bodies, Microgynon ED and other combined oral contraceptive pills do not protect against sexually transmitted infections (STIs), including HIV/AIDS. A barrier method, such as a condom, is required for STI protection.


Q: Are there any long-term health risks associated with taking Microgynon ED for many years?

Regulatory documents indicate that the use of combined hormonal contraceptives is associated with a small but increased risk of rare, serious vascular events (such as blood clots, stroke, or heart attack). This risk is generally highest in the first year of use or when restarting the medication.


Q: How does Microgynon ED affect blood pressure?

Official warnings note that small increases in blood pressure have been observed in many women taking combined oral contraceptives. It is important to note that severe hypertension is listed as a contraindication for the use of this medicine.


Q: Does Microgynon ED affect cholesterol levels?

Regulatory documents imply that these hormones can influence lipid (fat) metabolism. They list conditions like severe dyslipoproteinaemia (a disorder of fat/cholesterol levels) as a contraindication, which suggests the medication can have an effect on a person's cholesterol profile.


Q: Is it common for your period to stop completely while on Microgynon ED?

While the expected bleeding is a scheduled withdrawal bleed, the complete absence of bleeding (amenorrhea) is a documented occurrence. If a scheduled bleed is missed, the official guidance often recommends checking for pregnancy before continuing with the next pack.


Q: What types of medications are known to reduce the effectiveness of Microgynon ED?

Certain medications are known to interact by increasing the clearance of the contraceptive hormones, thereby reducing efficacy. Regulatory documents cite substances that act as enzyme inducers, such as some anti-epileptic drugs and the herbal product St. John’s Wort.


Q: Does Microgynon ED affect the results of blood tests?

Yes, the hormones in combined oral contraceptives can influence the results of certain laboratory tests. These can include tests related to liver, thyroid, adrenal, and renal function, as well as blood-clotting and binding protein parameters.


Q: Is it necessary to use a backup method of contraception when starting Microgynon ED?

According to the official prescribing information, if the pill is started after Day 5 of the menstrual cycle, a non-hormonal backup method (such as condoms) is generally required for the first 7 days of active pill intake to ensure protection.


Q: Is the ED formulation designed to improve compliance?

The Every Day regimen is often recognized for simplifying the daily schedule. By requiring a pill be taken continuously, without a break, this regimen can help improve user adherence to the schedule.


Q: Can Microgynon ED be taken by people with a history of migraines?

Microgynon ED is contraindicated if the user has or has had a migraine with focal neurological symptoms (migraine with aura). The official label notes that any type of migraine warrants careful consideration while using the pill.


Q: How often should check-ups be scheduled when using Microgynon ED?

Official guidance recommends regular medical follow-up while using this medication. This typically involves an annual check-up with a healthcare provider, which should include blood pressure and weight checks, and relevant health screenings.


Q: How does Microgynon ED affect the natural menstrual cycle?

The medication works by suppressing the natural cycle through the inhibition of ovulation. The hormonal intake overrides the body’s natural cycle, and the bleeding experienced during the inactive pill week is a scheduled withdrawal bleed, not a typical menstrual period.


Q: Is Microgynon ED associated with hair loss or hair thinning?

Official side effect profiles in some regulatory documents list both hair loss and/or hair growth as a common adverse reaction. This effect is documented as a common adverse reaction in some regulatory side effect profiles.


Q: Are there any warnings about sun exposure while using Microgynon ED?

Some official packaging information includes a warning that the pill may cause or worsen a condition called chloasma (dark patches/pigmentation on the skin). Women who are prone to this condition are advised to avoid excessive exposure to sun or UV radiation.

How should Microgynon ED be stored and disposed of?

Storage Requirements

Official regulatory documents define strict storage conditions for Microgynon ED to maintain the stability of its hormonal components. The tablets must be stored below 30°C (or 25 C, depending on the specific formulation) and in a cool, dry place. The medicine must be kept in its original blister pack until the time of use; using the product past the expiry date printed on the carton is prohibited. It is mandatory that the product be stored out of the sight and reach of children.

Storage Constraint Required Action
Temperature Limit Store below 30 C (or 25 C)
Packaging Keep in original blister pack
Access Keep out of the sight and reach of children

Official Disposal Instructions

Expired or unused Microgynon ED must be disposed of via specialized channels. Regulatory labeling prohibits discarding the product in wastewater or regular household trash. The official instruction is to return the unused or expired medicine to a pharmacist for safe and appropriate pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microgynon ED found in:

A-Z Index: